The US Drug Enforcement Administration (DEA) has withdrawn its proposal to effectively ban five psychedelic compounds after receiving significant opposition from the research and advocacy community
Psychedelics are having another moment in the spotlight. But is the heightened awareness just hype, or have these once-taboo substances been permanently rehabilitated?
Biotechnology firm Awakn Life Sciences has secured UK government funding to accelerate the route to the UK and US markets for its proprietary ketamine-assisted therapy, which is designed to treat alcohol use disorder
As the first federally approved psychedelics clinical trial begins in the US, there is broad but not total agreement among official bodies over legalising research into hallucinogenic substances
Strangely, Brexit and then the Covid-19 pandemic have combined to create ideal conditions for the UK to potentially become a leader in psychedelics research
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
